Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 113

Related Citations for PubMed (Select 23494240)

1.

Comprehensive assessment of the association of ERCC2 Lys751Gln polymorphism with susceptibility to cutaneous melanoma.

Dong Y, Zhuang L, Ma W.

Tumour Biol. 2013 Apr;34(2):1155-60. doi: 10.1007/s13277-013-0657-7. Epub 2013 Feb 3.

PMID:
23494240
2.

Quantitative assessment of the association between XPC Lys939Gln polymorphism and cutaneous melanoma risk.

Zhou L, Lu Y, Yang G, Wu J.

Tumour Biol. 2014 Feb;35(2):1427-32. doi: 10.1007/s13277-013-1196-y. Epub 2013 Nov 26.

PMID:
24277375
3.

XPD Lys751Gln polymorphism and esophageal cancer susceptibility: a meta-analysis of case-control studies.

Ding DP, Ma WL, He XF, Zhang Y.

Mol Biol Rep. 2012 Mar;39(3):2533-40. doi: 10.1007/s11033-011-1005-x. Epub 2011 Jun 11.

PMID:
21667112
4.

ERCC2 Lys751Gln polymorphism is associated with lung cancer among Caucasians.

Zhang J, Gu SY, Zhang P, Jia Z, Chang JH.

Eur J Cancer. 2010 Sep;46(13):2479-84. doi: 10.1016/j.ejca.2010.05.008. Epub 2010 Jun 3. Review.

PMID:
20627704
5.

Genetic polymorphisms of xeroderma pigmentosum group D gene Asp312Asn and Lys751Gln and susceptibility to prostate cancer: a systematic review and meta-analysis.

Ma Q, Qi C, Tie C, Guo Z.

Gene. 2013 Nov 10;530(2):309-14. doi: 10.1016/j.gene.2013.08.053. Epub 2013 Aug 23. Review.

PMID:
23973729
6.

A pooled analysis of the ERCC2 Asp312Asn polymorphism and esophageal cancer susceptibility.

Wen F, Zhao Z, Liu C, Yin Q, Weng J, Wang Y, Ma Y.

Tumour Biol. 2014 Apr;35(4):2959-65.

PMID:
24234258
7.

Polymorphisms of excision repair gene XPD Lys751Gln and hOGG1 Ser326Cys might not be associated with hepatocellular carcinoma risk: a meta-analysis.

Zhang RC, Mou SH.

Tumour Biol. 2013 Apr;34(2):901-7. doi: 10.1007/s13277-012-0625-7. Epub 2012 Dec 28.

PMID:
23271362
8.

Lack of association between XPD Lys751Gln and Asp312Asn polymorphisms and colorectal cancer risk: a meta-analysis of case-control studies.

Zhang Y, Ding D, Wang X, Zhu Z, Huang M, He X.

Int J Colorectal Dis. 2011 Oct;26(10):1257-64. doi: 10.1007/s00384-011-1222-8. Epub 2011 May 4.

PMID:
21541661
9.

XPD Lys751Gln polymorphism and esophageal cancer risk: a meta-analysis involving 2288 cases and 4096 controls.

Yuan L, Cui D, Zhao EJ, Jia CZ, Wang LD, Lu WQ.

World J Gastroenterol. 2011 May 14;17(18):2343-8. doi: 10.3748/wjg.v17.i18.2343.

10.

Association between XPD Lys751Gln polymorphism and risk of head and neck cancer: a meta-analysis.

Yuan H, Niu YM, Wang RX, Li HZ, Chen N.

Genet Mol Res. 2011 Nov 22;10(4):3356-64. doi: 10.4238/2011.November.22.6.

11.

XPD Lys751Gln and Asp312Asn polymorphisms and gastric cancer susceptibility: a meta-analysis of case-control studies.

Yin QH, Liu C, Hu JB, Meng RR, Li L, Wang YJ.

Asian Pac J Cancer Prev. 2013;14(1):231-6.

12.

XPD Lys751Gln polymorphism and breast cancer susceptibility: a meta-analysis involving 28,709 subjects.

Qiu LX, Yao L, Zhang J, Zhu XD, Zhao XM, Xue K, Mao C, Chen B, Zhan P, Yuan H, Hu XC.

Breast Cancer Res Treat. 2010 Nov;124(1):229-35. doi: 10.1007/s10549-010-0813-3. Epub 2010 Mar 5.

PMID:
20204500
13.

Association of XPD Lys751Gln polymorphism with head and neck cancer susceptibility: evidence from 11,443 subjects.

Lin H, Lin D, Zheng C.

Diagn Pathol. 2014 Jan 20;9:15. doi: 10.1186/1746-1596-9-15.

14.

Meta-analysis of two ERCC2 (XPD) polymorphisms, Asp312Asn and Lys751Gln, in breast cancer.

Pabalan N, Francisco-Pabalan O, Sung L, Jarjanazi H, Ozcelik H.

Breast Cancer Res Treat. 2010 Nov;124(2):531-41. doi: 10.1007/s10549-010-0863-6. Epub 2010 Apr 9.

PMID:
20379847
15.

Complex association between ERCC2 gene polymorphisms, gender, smoking and the susceptibility to bladder cancer: a meta-analysis.

Wu Y, Yang Y.

Tumour Biol. 2014 Jun;35(6):5245-57. doi: 10.1007/s13277-014-1682-x. Epub 2014 Feb 7.

PMID:
24504678
16.

Association between ERCC2 Lys751Gln polymorphism and lung cancer risk: a meta-analysis involving 23,370 subjects.

Tan X, Xian L, Chen X, Shi L, Wang Y, Guo J, Liang G, Zhao Z, Chen M.

Twin Res Hum Genet. 2014 Apr;17(2):99-107. doi: 10.1017/thg.2014.4. Epub 2014 Feb 20.

PMID:
24556168
17.

XPD Lys751Gln polymorphism is not associated with oral cancer risk: evidence from a meta-analysis.

Cui J, Li D, Shen L, Zhang W, Xu X.

Tumour Biol. 2014 Jul;35(7):6335-41. doi: 10.1007/s13277-014-1835-y. Epub 2014 Mar 22.

PMID:
24652592
18.

Comprehensive assessment of associations between ERCC2 Lys751Gln/Asp312Asn polymorphisms and risk of non- Hodgkin lymphoma.

Zhou JY, He LW, Liu J, Yu HL, Wei M, Ma WL, Shi R.

Asian Pac J Cancer Prev. 2014;15(21):9347-53.

19.

XPD gene polymorphism and host characteristics in the association with cutaneous malignant melanoma risk.

Baccarelli A, Calista D, Minghetti P, Marinelli B, Albetti B, Tseng T, Hedayati M, Grossman L, Landi G, Struewing JP, Landi MT.

Br J Cancer. 2004 Jan 26;90(2):497-502.

20.

Xeroderma pigmentosum complementation group D (XPD) gene polymorphisms contribute to bladder cancer risk: a meta-analysis.

Li SX, Dai QS, Chen SX, Zhang SD, Liao XY, Deng X, Chi HB, Li FJ, Zhu JH, Jiang YY.

Tumour Biol. 2014 Apr;35(4):3905-15. doi: 10.1007/s13277-013-1519-z. Epub 2013 Dec 18.

PMID:
24347488
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk